Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with ...
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic ...
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing, commends the updated Prostate Cancer Guidelines from the National ...
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital ...
Prostate Cancer is the second leading cause of death in American men after lung cancer. In 2018, 165,000 men will be diagnosed with prostate cancer. The question all men with prostate cancer need ...
Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025
Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results